The importance of drug-drug interactions in the DAA era

Digestive and Liver Disease

Volumn 45, Issue S5, 2013, Pages

  Back, David ^a   Else, Laura ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Boceprevir; Drug drug interactions; Hepatitis C virus infection; Pharmacokinetics; Telaprevir

Indexed keywords

ABT 450; ASUNAPREVIR; ATAZANAVIR PLUS RITONAVIR; BOCEPREVIR; CYCLOSPORIN; CYTOCHROME P450 3A4; DACLATASVIR; DANOPREVIR; DARUNAVIR; DEXTROMETHORPHAN; EFAVIRENZ; EMTRICITABINE; ESCITALOPRAM; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; FALDAPREVIR; FILIBUVIR; KETOCONAZOLE; LOSARTAN; METHADONE; MIDAZOLAM; OMEPRAZOLE; RALTEGRAVIR; RANITIDINE; RILPIVIRINE; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TEGOBUVIR; TELAPREVIR; TENOFOVIR; WARFARIN;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; REVIEW;

AKR; ALDO-KETOREDUCTASES; AREA UNDER THE PLASMA CONCENTRATION VS. TIME CURVE; AUC; BID; BOC; BOCEPREVIR; CYP; CYTOCHROME P450; DAAS; DIRECT-ACTING ANTIVIRALS; DRUG-DRUG INTERACTIONS; HCV; HEPATITIS C VIRUS; HEPATITIS C VIRUS INFECTION; HIV; HUMAN IMMUNODEFICIENCY VIRUS; IFN; INTERFERON; P-GLYCOPROTEIN; P-GP; PHARMACOKINETICS; RBV; RIBAVIRIN; SPCS; SUMMARY OF PRODUCT CHARACTERISTICS; TELAPREVIR; TVR; TWICE DAILY; UDP-GLUCURONOSYLTRANSFERASE; UGT;

ANTIVIRAL AGENTS; CYTOCHROME P-450 CYP3A; DATABASES, PHARMACEUTICAL; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; INTERNET; OLIGOPEPTIDES; PROLINE;

EID: 84884718503     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.07.008     Document Type: Review

References (41)

1. Burger D., Back D., Buggisch P., et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. Journal of Hepatology 2013, 58:792-800.
2. Kiser J.J., Burton J.R., Anderson P.L., et al. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012, 55:1620-1628.
3. Kiser J.J., Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annual Review of Pharmacology and Toxicology 2013, 53:427-449.
4. van Heeswijk R.P., Beumont M., Kauffman R.S., et al. Review of drug interactions with telaprevir and antiretrovirals. Antiviral Therapy 2013, 10.3851/IMP2527.
5. Garg V., Kauffman R.S., Beaumont M., et al. Telaprevir: pharmacokinetics and drug interactions. Antiviral Therapy 2012, 17:1211-1221.
6. Rodriguez-Torres M. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. Current Opinion in Infectious Diseases 2013, 26:50-57.
7. http://www.hep-druginteractions.org/.
8. Summary of Product Characteristics, Victrelis 200mg hard capsules. http://www.medicines.org.uk/EMC/medicine/24768/SPC/Victrelis+200+mg+hard+capsules/2013.
9. Ghosal A., Yuan Y., Tong W., et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2011, 39:510-521.
10. Marcellin P., Forns X., Goeser T., et al. Telaprevir is effective given every 8 or 12hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011, 140:459-468. e1; quiz e14.
11. Buti M., Agarwal K., Horsmans Y. OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8hours in treatment-naive, genotype 1 HCV infected patients. Hepatology 2012, 56:191A-1144A.
12. van Heeswijk R., Boogaerts G., de Paepe E., et al. The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor telaprevir. Reviews in Antiviral Therapy & Infectious Diseases 2011, 6:21.
13. Garg V., Chandorkar G., Farmer H.F., et al. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. Journal of Clinical Pharmacology 2012, 52:1566-1573.
14. Summary of Product Characteristics, INCIVO 375mg film coated tablets. http://www.medicines.org.uk/EMC/medicine/25038/SPC/INCIVO+375+mg+film+coated+tablets/2012.
15. INCIVEK Film Coated Tablets, Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf2013.
16. VICTRELIS Capsules, Prescribing Information. http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf2013.
17. Muller F., Fromm M.F. Transporter-mediated drug-drug interactions. Pharmacogenomics 2011, 12:1017-1037.
18. Kunze A., Huwyler J., Camenisch G., et al. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochemical Pharmacology 2012, 84:1096-1102.
19. Hulskotte E., Gupta S., Xuan F., et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012, 56:1622-1630.
20. Burton J.R., Everson G.T. Management of the transplant recipient with chronic hepatitis C. Clinics in Liver Disease 2013, 17:73-91.
21. Werner C.R., Egetemeyr D.P., Lauer U.M., et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2012, 18:1464-1470.
22. Coilly A., Furlan V., Roche B., et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrobial Agents and Chemotherapy 2012, 56:5728-5734.
23. Lee J.E., van Heeswijk R., Alves K., et al. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrobial Agents and Chemotherapy 2011, 55:4569-4574.
24. Hulskotte E., Gupta S., Xuan Y., et al. Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor and the HMG-CoA reductase inhibitors atorvastatin and pravastatin. 16th Annual Meeting of HEP DART 2011.
25. Summary of Product Characteristics, Zyban 150mg prolonged release film-coated tablets. http://www.medicines.org.uk/EMC/medicine/2948/SPC/Zyban+150+mg+prolonged+release+film-coated+tablets/2012.
26. Hulskotte E., Gupta S., Xuan Y., et al. Co-administration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. 16th Annual Meeting of HEP DART 2011.
27. Hulskotte E.G., Feng H.P., Xuan F., et al. Pharmacokinetic interactions between the hepatitis c virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clinical Infectious Diseases 2013, 56:718-726.
28. Sulkowski M.S. HCV therapy in HIV-infected patients. Liver International 2013, 33:63-67.
29. Jennings C.L., Sherman K.E., Hepatitis C. HIV co-infection: new drugs in practice and in the pipeline. Current HIV/AIDS Reports 2012, 9:231-237.
30. Sulkowski M.S. Current management of hepatitis C virus infection in patients with HIV co-infection. The Journal of Infectious Diseases 2013, 207(Suppl. 1):S26-S32.
31. Schwarze-Zander C., Rockstroh J.K. HIV protease inhibitors in combination with boceprevir: are drug-drug interactions the same for all patients. AIDS 2012, 26:1845-1846.
32. Sabo J.P., Kashuba A.D., Ballow C.H., et al. Cytochrome P450 (CYP) interactions with the HCV protease inhibitor BI 201335 in healthy volunteers 2012, ICAAC, San Francisco, CA. 52nd ed.
33. Sekar V., Verloes R., Meyvisch P., et al. Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers. 45th Annu Meet Eur Assoc Study Liver (EASL) 2010.
34. Bernstein B., Menon R.M., Klein C.E., et al. Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers 2009, HEP DART, Kohala Coast, Hawaii.
35. Eley T., Gardiner D., Persson A., et al. Evaluation of drug interaction potential of the HCV protease inhibitor asunaprevir (ASV; BMS-650032) at 200mg twice daily (BID) in metabolic cocktail and P-glycoprotein (P-gp) probe studies in healthy volunteers. 62nd Am Assoc Study Liver Dis 2011.
36. Chang L., Zhang Y., Weigl P., et al. Danoprevir does not change the effect of ritonavir on the pharmacokinetics of cytochrome P450 3A substrate midazolam or the CYP2C9 substrate warfarin. 112th Annu Meet Am Soc Clin Pharmacol Ther. 2011.
37. Purohit V.S., Fairman D., Fang J., et al. Evaluation of CYP3A mediated drug interactions for fi{ligature}libuvir in healthy volunteers: fi{ligature}libuvir as an object and precipitant. Am Soc Clin Pharmacol Ther 2010.
38. Bavisotto L., Wang C., Jacobson I.M., et al. Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype1 infected patients. 58th Annu Meet Am Assoc Study Liver Dis 2007.
39. Maring C., Wagner R., Hutchison D., et al. Preclinical potency, pharmacokinetic and ADME characterization of ABT-333, a novel non-nucleoside HCV polymerase inhibitor. 44th Annu Meet Eur Assoc Study Liver (EASL) 2009.
40. Bifano M., Sevinsky H., Persson A., et al. Daclatasvir has no clinically signifi{ligature}cant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects. 62nd Am Assoc Study Liver Dis 2011.
41. Denning J., Cornpropst M., Clemons D., et al. Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone pharmacokinetics and pharmacodynamics. 62nd Am Assoc Study Liver Dis 2011.